<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03130491</url>
  </required_header>
  <id_info>
    <org_study_id>CLP002-2016</org_study_id>
    <nct_id>NCT03130491</nct_id>
  </id_info>
  <brief_title>European Study Evaluating the EMBLOK Embolic Protection System During TAVR</brief_title>
  <official_title>European Study Evaluating the EMBLOK Cerebral Embolic Protection System During Transcatheter Aortic Valve Replacement (TAVR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovative Cardiovascular Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Meditrial Europe Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Innovative Cardiovascular Solutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the performance and the treatment effect of the use of&#xD;
      the Emblok embolic protection system use during transcatheter aortic valve replacement with&#xD;
      respect to procedure-related cerebral embolic burden as determined by DW-MRI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The enrollment of up to thirty subjects with severe native aortic valve stenosis who meet&#xD;
      clinically approved indications for transcatheter aortic valve replacement. The primary&#xD;
      objective evaluates performance and treatment effect of the use of the EMBLOK. A secondary&#xD;
      objective of this study is to analyze the safety profile and the type of captured debris from&#xD;
      the Emblok filter after TAVR. Due to the small sample size, the study is not powered to&#xD;
      detect a reduction in actual stroke rates. However, the potential risk of stroke will be&#xD;
      assessed based on neurological evaluations pre and post procedure. In addition, silent&#xD;
      ischemic damage and cerebral embolic burden will be assessed using DW MRI studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2017</start_date>
  <completion_date type="Anticipated">December 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance Endpoint</measure>
    <time_frame>Day 1 to post procedure</time_frame>
    <description>successful insertion, placement and removal of the EMBLOK system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint (Rate of MACCE)</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of MACCE</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Efficacy Endpoint</measure>
    <time_frame>2-5 days</time_frame>
    <description>Reduction in embolic burden as measured by DW-MRI at baseline compared to post procedure 2-5 days</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Aortic Valve Disease</condition>
  <arm_group>
    <arm_group_label>TAVR + Embolic protection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>subjects with severe native aortic valve stenosis who meet the commercially approved indications for transcatheter aortic valve replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transcatheter Aortic Valve Replacement (TAVR)</intervention_name>
    <description>placement of a filter to capture and remove embolic material from entering the cerebral vascular circulation during aortic valve replacement</description>
    <arm_group_label>TAVR + Embolic protection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EMBLOK filter</intervention_name>
    <description>Embolic Filter Protection System During TAVR</description>
    <arm_group_label>TAVR + Embolic protection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Subject is between 18 and 90 years of age.Subject is scheduled to&#xD;
        undergo transcatheter aortic valve replacement (TAVR) procedure on a native aortic valve&#xD;
        and is qualified based on pre-operative trans-thoracic echocardiogram (TTE). Subject&#xD;
        anatomy is compatible with correct device positioning with: Iliofemoral access compatible&#xD;
        with a 12 French arterial access system for the EMBLOK catheter (&gt; 4 mm vessel diameter).&#xD;
        Ascending aorta length greater than or equal to 9 cm. Ascending aorta/aortic arch diameter&#xD;
        less than or equal to 35mm.&#xD;
&#xD;
        Female subjects of child bearing potential must have a negative pregnancy test within 48&#xD;
        hours prior to the index study procedure.Subject agrees to comply with all study required&#xD;
        visits. Subject or subject's legal representative completes written Informed Consent.&#xD;
&#xD;
        Exclusion Criteria: Subject requires an emergent procedure. Contraindications to MRI&#xD;
        including: Subjects with any non-MRI compatible implantable temporary or permanent&#xD;
        pacemaker or defibrillator, metal implants in field of view, metallic fragments, clips, or&#xD;
        devices in the brain or eye before TAVI procedure, claustrophobia, planned implantation of&#xD;
        non-MRI compatible pacemaker or implantable cardioverter defibrillator within 30 days after&#xD;
        TAVR.&#xD;
&#xD;
        Subject has experienced a myocardial infarction within 30 days of the planned index&#xD;
        procedure.&#xD;
&#xD;
        Subject has renal insufficiency, defined as a creatinine level &gt; 2.5 mg/dl at the time of&#xD;
        treatment.&#xD;
&#xD;
        Subject has documented history of stroke or TIA within prior 3 months. Subject has an&#xD;
        ejection fraction of 30% or less. Subject has a history of intolerance, allergic reaction&#xD;
        or contraindication to any of the study medications, including heparin, aspirin,&#xD;
        clopidogrel or a sensitivity to contrast media or anesthesia which cannot be adequately&#xD;
        pre-treated.&#xD;
&#xD;
        Subject has known allergy to any materials used in the EMBLOK device or allergy to&#xD;
        intravascular contrast agents that cannot be pre-medicated.&#xD;
&#xD;
        Subject has active endocarditis or an ongoing systemic infection defined as fever within&#xD;
        temperature &gt; 38Â° C and/ or WBC &gt; 15,000 IU.&#xD;
&#xD;
        Subjects undergoing therapeutic thrombolysis. Subject has history of bleeding diathesis or&#xD;
        a major coagulopathy. Subject is known or suspected to be pregnant, or is lactating.&#xD;
        Subject is currently participating in another drug or device clinical study, or has other&#xD;
        medical illnesses that may cause the subject to be non-compliant with the protocol or&#xD;
        confound the data interpretation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Azeem Latib, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Raffaele</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monica Tocchi</last_name>
    <phone>+41791054396</phone>
    <email>monica@meditrial.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Minarsch</last_name>
    <phone>+9492805700</phone>
    <email>laura22@mmc-medical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital San Donato</name>
      <address>
        <city>Milan</city>
        <state>Milano</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico De Marco, MD</last_name>
      <phone>+393286242014</phone>
      <email>federico.demarco@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Giovanni Bianchi</last_name>
      <phone>+393286242014</phone>
      <email>giova30.bianchi@yahoo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Federico DeMarco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vega Rusconi</last_name>
      <phone>+39026437331</phone>
      <email>rusconi.vega@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>paolo vezzulli</last_name>
      <phone>+390226437331</phone>
      <email>vezzulli.paolo@hsr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Matteo Montorfano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 11, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

